Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Monovisc is a high molecular weight hyaluronan injection used for treating osteoarthritis pain in the knee. It's a viscosupplement that supplements the hyaluronic acid naturally found in synovial fluid of healthy joints. ## Composition and Properties Monovisc consists of high molecular weight (1-2.9 million Daltons), ultra-pure, natural hyaluronan derived from bacterial fermentation (Streptococcus equi)[1][4]. It's cross-linked with a proprietary cross-linker and dissolved in physiologic saline[1][4]. Each pre-filled syringe contains 4 mL of Monovisc with 88 mg of hyaluronan (nominal), which is equivalent to three injections of Orthovisc[1][4]. ## Indications Monovisc is FDA-approved for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics like acetaminophen[1][2][3]. In the European Economic Area, it's indicated as a viscoelastic supplement or replacement for synovial fluid in human knee joints[5]. Some regions have expanded indications to include hip, shoulder, and ankle joints[6]. ## Mechanism of Action Hyaluronic acid works by: - Providing lubrication and mechanical support in the joints - Acting as a shock absorber - Reducing nerve impulses and sensitivity of nociceptive nerve endings (analgesic effect) - Reducing joint inflammation - Protecting cartilage (chondroprotective effect)[6][8] ## Administration Monovisc is administered as a single intra-articular injection into the affected knee joint[9]. This single-injection approach differentiates it from some other viscosupplements that require multiple injections. The convenience of a single injection is one of its key benefits[5][9]. ## Effectiveness Pain relief from Monovisc can be felt as early as 2 weeks following the injection and may last up to 6 months[5][8]. Clinical studies have shown that a second injection six months after the first is safe[6]. ## Contraindications Monovisc should not be administered to patients with: - Known hypersensitivity to hyaluronate preparations - Known hypersensitivity to gram-positive bacterial proteins - Infections or skin diseases in the area of the injection site or joint - Known systemic bleeding disorders[7][9] ## Side Effects Common side effects may include transient pain, swelling, heat, rash, itching, bruising, and redness at the injection site. These reactions are typically mild and temporary[9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Monovisc.